You just read:

Benefitting From Expanded Access in Europe, Roche's Ocrevus is on Track to Displace Biogen's Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months

News provided by

Spherix Global Insights

Oct 07, 2019, 04:47 ET